Telmisartan
ApprovedTerminated 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Arterial Hypertension
Conditions
Arterial Hypertension, Diabetes Mellitus Type 2 IRC or NIR
Trial Timeline
Dec 1, 2007 → Jan 1, 2009
NCT ID
NCT00559286About Telmisartan
Telmisartan is a approved stage product being developed by Bayer for Arterial Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT00559286. Target conditions include Arterial Hypertension, Diabetes Mellitus Type 2 IRC or NIR.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00559286 | Approved | Terminated |
Competing Products
20 competing products in Arterial Hypertension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CS1 Administration | Cereno Scientific | Phase 2 | 47 |
| CS1 | Cereno Scientific | Pre-clinical | 18 |
| Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | Keros Therapeutics | Phase 2 | 44 |
| Satralizumab (Genetical Recombination) | Chugai Pharmaceutical | Phase 2 | 52 |
| Sarpogrelate SR + Sarpogrelate | Yuhan | Approved | 85 |
| edoxaban + Clopidogrel + Aspirin | Daiichi Sankyo | Phase 2 | 52 |
| tadalafil and ambrisentan upfront combination therapy | Eli Lilly | Approved | 85 |
| Tadalafil- Tablet or Oral suspension | Eli Lilly | Phase 1/2 | 41 |
| tadalafil | Eli Lilly | Pre-clinical | 23 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| NS-863 Low Dose + NS-863 High Dose + NS-863 Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Olaparib | AstraZeneca | Phase 1/2 | 41 |
| SCH 530348 | Merck | Phase 2 | 52 |
| MK-8892 + Placebo for MK-8892 | Merck | Phase 1 | 33 |
| Riociguat | Merck | Approved | 85 |
| Sotatercept | Merck | Approved | 85 |
| Sotatercept + Background PAH Therapy | Merck | Phase 2 | 52 |
| Sotatercept + Placebo + Background PAH Therapy | Merck | Phase 3 | 77 |
| Sotatercept | Merck | Phase 3 | 77 |
| Sotatercept | Merck | Phase 3 | 77 |